Pulmonx Q2 Loss Narrows on Cost Cuts, but Revenue Slips 5%; CEO Adopts 10b5-1 Plan
LUNG sits 73% above its 52-week low of $1.13 on elevated volume (1.9× avg).
Summary
Pulmonx reported a narrower Q2 loss on cost cuts, but revenue slipped 5% to $22.8M. CEO Glendon French adopted a 10b5-1 plan to sell up to 360,000 shares.
Key Events · Earnings and Guidance · LUNG
-
Q2 Revenue Declines 5%
Revenue fell to $22.8M from $23.9M a year ago, driven by lower Zephyr Valve procedure volumes in the U.S. and a halt in China sales pending registration renewal.
-
Net Loss Narrows 34%
Net loss improved to $10.1M ($0.24/share) from $15.2M ($0.38/share), helped by a 16% drop in operating expenses and a 590 bps gross margin expansion to 78.0%.
-
CEO Adopts 10b5-1 Trading Plan
CEO Glendon French adopted a Rule 10b5-1 plan on June 11, 2026 to sell up to 360,000 shares, expiring August 13, 2027.
-
China Registration Renewed
The Chinese registration certificate was renewed in June 2026; the company expects to restart commercial activity and resume distributor shipments by early next year.
Analysis · LUNG · Industrial Applications And Services
Pulmonx's Q2 results present a mixed picture. Revenue declined 5% to $22.8M, pressured by headwinds in China, yet cost discipline drove a 34% narrower net loss and gross margin expansion to 78%. The balance sheet remains strained with $55.8M in cash against a $545M accumulated deficit, though management asserts sufficient liquidity for the next 12 months. Separately, CEO Glendon French adopted a 10b5-1 plan to sell up to 360,000 shares—a notable insider disposition signal. The renewal of the China registration certificate provides a potential catalyst for international revenue recovery.
At the time of this filing, LUNG was trading at $1.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $87M. The 52-week trading range was $1.13 to $2.89. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.